12278 Scripps Summit Drive
San Diego, CA 92131
United States
858 875 1800
https://www.fatetherapeutics.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 181
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. J. Scott Wolchko | Founder, CEO, President & Director | 645k | 3,85M | 1970 |
Mr. Edward J. Dulac III | Chief Financial Officer | 455k | N/D | 1976 |
Ms. Cindy R. Tahl J.D. | General Counsel, Corporate Secretary & Compliance Officer | 455k | 3,89M | 1973 |
Dr. Bahram Valamehr Ph.D. | Chief Research & Development Officer | 455k | 1,39M | 1977 |
Mr. Jim Beitel M.B.A. | Senior Vice President of Corporate Development | N/D | N/D | N/D |
Dr. Jerome Bressi Ph.D. | Senior Vice President of Regulatory & Quality | N/D | N/D | N/D |
Dr. Barbara Hickingbottom | Senior VP of Clinical Development | N/D | N/D | N/D |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
L'ISS Governance QualityScore di Fate Therapeutics, Inc. al 1 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 5; diritti degli azionisti: 8; retribuzione: 7.